ESTRO 2024 - Abstract Book

S4887

Physics - Quality assurance and auditing

ESTRO 2024

Conclusion:

The study showed that dose delivery achieved with protons was robust for the primary target coverage. Also for the elective target, a clinically acceptable dose delivery robustness was observed. The study showed that MFO proton plans with simultaneously integrated boost to the prostate and pelvic lymph nodes are robust to day-to-day anatomical variation. We have now moved to the randomised phase of the PROstate PROTON Trial 1, which is actively including patients.

Keywords: Prostate cancer, proton therapy, robustness

2430

Digital Poster